Evolução clínica de um grupo de pacientes com TB multirresistente atendidos em um centro de referência na cidade do Rio de Janeiro

Siqueira, Helio Ribeiro de; Freitas, Flávia Alvim Dutra de; Oliveira, Denise Neves de; Barreto, Angela Maria Werneck; Dalcolmo, Margareth Pretti; Albano, Rodolpho Mattos.
J. bras. pneumol ; 35(1): 54-62, jan. 2009. graf, tab
Artigo em Inglês, Português | LILACS | ID: lil-506067

Documentos relacionados

  1. Association of indicators of extensive disease and rifampin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis.
  2. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
  3. Pharmacodynamics and Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis.
  4. [Expert consensus on surgical treatment of multidrug-resistant and rifampicin-resistant pulmonary tuberculosis in China (2022 edition)].
  5. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
  6. Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China.
  7. Influence of COVID-19 on the notification of drug-resistant pulmonary tuberculosis cases.
  8. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
  9. [Evaluation of the performance of InnowaveDX MTB/RIF for the detection of <i>Mycobacterium tuberculosis</i> complex and rifampicin resistance].
  10. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.